Meghmani Finechem Ltd - 543332 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Epigral Limited (Formerly known as Meghmani Finechem Limited'') [''the Company''] informs that the Company is having One-on-one Meetings on 17th August, 2023. Meghmani Finechem Ltd - 543332 - Announcement under Regulation 30 (LODR)-Investor Presentation
Epigral Limited (Formerly known as Meghmani Finechem Limited'') submits Corporate Presentation. Meghmani Finechem Ltd - 543332 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Epigral Limited (Formerly known as Meghmani Finechem Limited) gives intimation of participation in Emkay Confluence - Investor Conference scheduled to be held on 17th August, 2023. Meghmani Finechem Ltd - 543332 - Intimation Of Submission Of Application For Reclassification To Stock Exchanges.
Epigral Limited (Formerly known as Meghmani Finechem Limited) informs about submission of Application for Reclassification to Stock Exchanges on 10th August, 2023. Meghmani Finechem Ltd - 543332 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Epigral Limited (formerly known as Meghmani Finechem Limited) submits Transcript of Earnings Call for Q1 FY24 - Results Meghmani Finechem Ltd - 543332 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Epigral Limited (formerly known as Meghmani Finechem Limited) informs about one-on-one meeting with Solidarity Advisors Private Limited on 11th August, 2023. Meghmani Finechem Ltd - 543332 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Epigral Limited (Formerly known as Meghmani Finechem Limited) submits the link of audio recording of Earnings Call for Q1 FY24.
Meghmani Finechem Results Earnings Call for Q1FY24
Conference Call with Meghmani Finechem Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript. Q1FY24 Quarterly Result Announced for Meghmani Finechem Ltd.
Specialty chemicals company Meghmani Finechem announced Q1FY24 results: Revenue from operations of Rs 455 crore in Q1FY24 compared to Rs 533 crore in Q1FY23, down 15% YoY EBITDA of Rs 95 crore in Q1FY24 compared to Rs 187 crore in Q1FY23, down 49% YoY PAT of Rs 32 crore in Q1FY24 compared to Rs 108 crore in Q1FY23, down 71% YoY Commenting on the results Maulik Patel, Chairman and Managing Director, MFL said, “FY24 started with a quarter that witnessed global level slowdown and inventory destocking, impacting the chemical industry both at demand level and also at realization level. MFL too got impacted during the quarter gone by, on account of the drop in realizations. However, MFL achieved volume growth of 11% YoY in Q1FY24; this volume growth is in line with our expansion plans resulting in volume coming from CPVC Resin, Epichlorohydrin, and Hydrogen Peroxide. Revenue contribution from Derivatives and Specialty Chemical stood at 38% compared to 21% for a similar period last year. We estimate this volume growth story will continue further as these new projects will further contribute in FY24. Considering our long-term vision, we are on schedule for our expansions of CPVC Resin of 45,000 TPA and Chlorotoluene value chain, this will drive volume growth in FY25. Our R&D; centre is almost ready; hence we are ready with another strong pillar for our future growth in the Specialty Chemical segment. We believe that the current scenario is a phase that will pass and the long-term story remains intact. Hence, we are preparing ourselves for long-term growth and we are moving in that direction. Our board has taken the initiative to rename our company Epigral. This activity is proposed to strengthen our corporate brand in line with our commitment to transform the company as a global multi-product chemical conglomerate and enhance our reputation as an integral partner for esteemed clients and our stakeholders.” Result PDF
